Corvus Pharmaceuticals Inc. (CRVS)
NASDAQ
Closed
Oct 19, 2026
Day's Range
9.5052 wk Range
6.39Overview - CRVS - Corvus Pharmaceuticals Inc.
Key Statistics
Valuation
Enterprise Value
702.41M
P/E (Trailing)
-56.47
P/E (Forward)
-10.21
PEG Ratio
-0.62
Price / Book
4.06
EV / EBITDA
-12.35
Profitability
Profit Margin
0.00%
Operating Margin
0.00%
Return on Assets
-21.66%
Return on Equity
-35.43%
Ownership
Shares Outstanding
84.12M
Float
72.78M
Short % of Shares Outstanding
23.21%
Held by Insiders
3.50%
Held by Institutions
85.77%
Price stats
Beta
0.86
50-Day Avg
13.49
200-Day Avg
14.15
Dividends
Payout Ratio
0.00%
Analyst Consensus
8 analysts
Shariah Compliance
Report Date: Feb 17, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - CRVS - Corvus Pharmaceuticals Inc.
Peers - CRVS - Corvus Pharmaceuticals Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- CRVSNASDAQCorvus Pharmaceuticals Inc903.45MMarket Cap+36.03%52-week change-56.47P/E (Trailing)0.00%Profit Margin
- ARGXNASDAQArgenx SE51.51BMarket Cap-3.70%52-week change31.22P/E (Trailing)32.26%Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.31.02BMarket Cap-111.89%52-week change39.09P/E (Trailing)16.12%Profit Margin
- BNTXNASDAQBioNTech SE American Depositary Share22.13BMarket Cap-20.35%52-week change160.80P/E (Trailing)-63.63%Profit Margin
- ASNDNASDAQAscendis Pharma A/S16.01BMarket Cap+16.49%52-week change18.23P/E (Trailing)70.84%Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.12.97BMarket Cap+15.27%52-week change-17.56P/E (Trailing)-97.02%Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.10.58BMarket Cap+1.57%52-week change147.76P/E (Trailing)2.14%Profit Margin
Profile Summary - CRVS - Corvus Pharmaceuticals Inc.
About
Corvus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing immunology and oncology therapies for immune-mediated diseases and cancer. Corvus Pharmaceuticals Inc. centers its current work on immune modulator product candidates that target pathways involved in immune cell activation,…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
